C9101 HCPCS code: Injection, oliceridine, 0.1 mg
C9101 is the HCPCS Level II code for injection, oliceridine, 0.1 mg. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. The NCCI unit limit is 300 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | D1A — Medical/surgical supplies |
| Added | 2022-10-01 |
| Last action effective | 2022-10-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 300 | CMS Policy |
| practitioner claims | 300 | CMS Policy |
What changed for C9101
- 2022-10-01: C9101 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9101?
C9101 is the HCPCS Level II code for injection, oliceridine, 0.1 mg. Short descriptor: "Inj, oliceridine 0.1 mg".
Does Medicare cover C9101?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
How many units of C9101 can be billed per day?
300 on outpatient hospital claims; 300 on practitioner claims (NCCI medically unlikely edits).
Related C91 codes
- C9113 — Injection, pantoprazole sodium, per vial
- C9121 — Injection, argatroban, per 5 mg
- C9122 — Mometasone furoate sinus implant, 10 micrograms (sinuva)
- C9132 — Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
- C9133 — Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.
- C9134 — Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.
- C9135 — Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.
- C9136 — Injection, factor viii, fc fusion protein, (recombinant), per i.u.
- C9137 — Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.
- C9138 — Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.
- C9139 — Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.
- C9140 — Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9101
- Watch C9101 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9101
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.